| Ytd | -13.11% | |
| 1y | -32.48% |
| Open | 1.09 | Prev Close | 1.09 | Low | 1.05 | High | 1.10 | Mkt Cap | 67.49M |
| Vol | 928.17K | Avg Vol | 527.53K | EPS | -1.81 | P/E | -0.60 | Forward P/E | -3.32 |
| Beta | 1.21 | Short Ratio | 15.30 | Inst. Own | 111.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.16 | 200-d Avg | 1.31 | 1yr Est | 40.18 |
PLRX News
Appointments bring global oncology drug development experience and deepen Board's operational and r
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 T
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with I
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral present
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLR
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) t
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median
Shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) have been assigned an average r
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Fr
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: P
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory
In February, we welcomed 17 new analysts to Seeking Alpha. This article showcases their stock picks
Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PL
Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) was the recipient of a large increase in
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its
One complete response and three partial responses observed in heavily pretreated ICI-secondary refr
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a c
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activi
During the session on Thursday, 461 stocks hit new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.